表紙
市場調查報告書

心律管理設備的全球市場 - 成長率,趨勢及預測(2019年∼2024年)

Cardiac Rhythm Management Devices Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 390617
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
Back to Top
心律管理設備的全球市場 - 成長率,趨勢及預測(2019年∼2024年) Cardiac Rhythm Management Devices Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年03月01日內容資訊: 英文 114 Pages
簡介

全球心律管理設備市場,預計在預測期間內以4.8%的年複合成長率成長。帶動市場成長的特定要素,有心血管障礙的罹患率上升,技術的進步,心臟監測的門診病人及居家照護的利用增加,及有利的償付方針等。

本報告提供全球心律管理設備市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等資訊總括性彙整。

目錄

第1章 簡介

  • 調查的成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 心血管障礙的罹患率上升
    • 技術的進步
    • 心臟監測的門診病人及居家照護的利用增加
    • 有利的償付政策
  • 市場阻礙因素
    • 對置入式心律設備的放射治療的效果
    • 設備的高成本
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭激烈度

第5章 市場區隔

  • 產品
    • 心臟去顫器
    • 心律調節器
    • 心臟再同步化治療設備
  • 地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Abbott
    • Abiomed
    • Biotronik SE & Co KG
    • Boston Scientific Corporation
    • Koninklijke Philips NV
    • LivaNova Plc
    • Medtronic PLC
    • SchillerAG
    • Shenzhen Mindray Biomedical Electronics Co., Ltd
    • Zoll Medical Corporation

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 54199

Market Overview

The cardiac rhythm management devices market is expected to witness a CAGR of 4.8% during the forecast period. Certain factors that are driving the market growth include the increasing prevalence of cardiovascular disorders, technological advancements, a rise in the use of ambulatory and home services for cardiac monitoring, and favorable reimbursement policies.

The increasing instance of cardiovascular disorders is one of the foremost factors driving the cardiac rhythm management devices market. According to the World Health Organization (WHO), globally, cardiovascular diseases account for more than 30% of deaths. Also, nearly 33.5 million people, globally, are suffering from atrial fibrillation (AFib), which is the most common type of serious arrhythmia. With the rise in the aging population in America and Europe, a number of patients suffering from heart rhythm disorders are likely to witness an increase and this is a cause for concern.

However, the therapeutic radiation used in cancer treatment can influence the operation of a patient with implantable cardiac rhythm devices. The implantable device technology uses complementary metal-oxide-semiconductor (CMOS) which are vulnerable to damage by the therapeutic doses of radiation, but it can vary according to the type of device in use. This factor is one of the major factors that limits the scope of using cardiac rhythm management devices, as the implants are highly sensitive and their malfunctioning may have serious consequences. On the other hand, the high cost of these devices with limited insurance coverage is limiting the growth of the market.

Scope of the Report

Cardiac rhythm management is a part of electrophysiology, which is used to manage the functioning of the heart. The last decade has observed an ongoing evolution and the use of cardiac rhythm management devices, including cardiac resynchronization therapy, pacemakers, implantable cardioverter defibrillators, and loop recorders. General practitioners (GP) are increasingly involved in the follow-up and management of patients with these devices.

Key Market Trends

Defibrillator is Expected to Hold the Largest Market Share in the Product Type

As per the American Heart Association (AHA), survival from cardiac arrest got doubled when bystanders used a publicly-available automated external defibrillator (AED) rather than just wait until emergency responders arrived. Bystanders used an AED in 18.8% of such cases. Cardiac arrest victims who received a shock from a publicly-available AED had far more chances of survival and being discharged from the hospital than those who did not, accounting for 66.5% versus 43%. Therefore, it has been estimated that about 1,700 lives are saved in the United States every year by bystanders using a defibrillator. This indicates that the usage of defibrillators has experienced a significant rise, globally, over the recent years.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to have the largest market share for cardiac rhythm management, due to the developed healthcare infrastructure, government initiatives, and rising incidence of arrhythmias demanding more cardiac implants. According to a report by the US CDC, more than 75,000 hospitalizations are attributed to atrial fibrillation. Also, it is highlighted that a large part of the American population suffers from atrial fibrillation. Therefore, it is expected to rise further in the forecast period.

Asia-Pacific is another region with high potential for this market, due to the rising healthcare expenditure by the government, the increasing the prevalence of cardiac disorders and the growing per capita income of the population in the South Asian countries.

Competitive Landscape

The cardiac rhythm management devices market is highly competitive and consists of a few major players. Companies like Abbott, Abiomed, Biotronik SE & Co KG, Boston Scientific Corporation, Koninklijke Philips NV, LivaNova Plc, Medtronic PPLC, SchillerAG, Shenzhen Mindray Biomedical Electronics Co. Ltd, and Zoll Medical Corporation, among others, hold the substantial market share in the cardiac rhythm management devices market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cardiovascular Disorders
    • 4.2.2 Technological Advancements
    • 4.2.3 Rise in the Use of Ambulatory and Home Servies for Cardiac Monitoring
    • 4.2.4 Favorable Reimbursement Policies
  • 4.3 Market Restraints
    • 4.3.1 Effects of Therapeutic Radiation on Implantable Cardiac Rhythm Devices
    • 4.3.2 High Cost of Devices
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Product
    • 5.1.1 Defibrillators
      • 5.1.1.1 Implantable Cardioverter Defibrillators (ICDS)
      • 5.1.1.1.1 Subcutaneous ICD (S-ICD)
      • 5.1.1.1.2 Transvenous ICD (T-ICD)
      • 5.1.1.2 External Defibrillators (ED)
      • 5.1.1.2.1 Manual External Defibrillators (MEDS)
      • 5.1.1.2.2 Automated External Defibrillators (AEDS)
    • 5.1.2 Pacemakers
      • 5.1.2.1 Implantable Pacemakers (ICPS)
      • 5.1.2.2 External Pacemakers
    • 5.1.3 Cardiac Resynchronization Therapy Devices
      • 5.1.3.1 Cardiac Resynchronization Therapy Defibrillators (CRT-D)
      • 5.1.3.2 Cardiac Resynchronization Therapy Pacemakers (CRT-P)
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 US
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 UK
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East & Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East & Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott
    • 6.1.2 Abiomed
    • 6.1.3 Biotronik SE & Co KG
    • 6.1.4 Boston Scientific Corporation
    • 6.1.5 Koninklijke Philips NV
    • 6.1.6 LivaNova Plc
    • 6.1.7 Medtronic PLC
    • 6.1.8 SchillerAG
    • 6.1.9 Shenzhen Mindray Biomedical Electronics Co., Ltd
    • 6.1.10 Zoll Medical Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top